| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GIP |
| Uniprot No | P09681 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-153aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSEKKEGHFSALPSLPVGSHAKVSSPQPR GPRYAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQREARA LELAGQANRKEEEAVEPQSSPAKNPSDEDLLRDLLIQELLACLLDQTNLC RLRSR |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GIP重组蛋白的3篇参考文献概览：
---
1. **《Recombinant expression and functional characterization of glucose-dependent insulinotropic polypeptide (GIP) in Escherichia coli》**
- **作者**: Smith A, et al.
- **摘要**: 本研究报道了在大肠杆菌中高效表达具有生物活性的重组GIP蛋白。通过优化密码子和纯化工艺，获得的GIP能有效激活细胞受体并促进胰岛素分泌，为糖尿病研究提供了经济制备方案。
2. **《A PEGylated GIP analogue with prolonged half-life improves glycemic control in diabetic mice models》**
- **作者**: Chen L, et al.
- **摘要**: 开发了一种聚乙二醇化修饰的重组GIP类似物，显著延长了血浆半衰期。动物实验表明其可持续改善血糖水平并减少脂肪堆积，提示其在代谢疾病治疗中的潜力。
3. **《Dual GIP/GLP-1 receptor agonists as novel therapeutics for obesity and diabetes》**
- **作者**: Finan B, et al.
- **摘要**: 研究设计了一种同时靶向GIP和GLP-1受体的重组双激动剂。相比单一受体激动剂，该分子在小鼠模型中表现出更强的减重和降糖效果，为开发新型代谢药物提供了方向。
---
注：上述文献为示例，实际引用时需核实具体文献来源及细节。如需精确检索，建议通过PubMed或Web of Science以“GIP recombinant protein”“GIP analog”为关键词查询。
**Background of GIP Recombinant Protein**
Glucose-dependent insulinotropic polypeptide (GIP), also known as gastric inhibitory polypeptide, is a 42-amino-acid hormone produced by K-cells in the duodenum and jejunum. It belongs to the incretin hormone family, alongside glucagon-like peptide-1 (GLP-1), and plays a critical role in metabolic regulation. GIP exerts its effects by binding to the GIP receptor (GIPR), a G protein-coupled receptor expressed in pancreatic beta cells, adipose tissue, bone, and the central nervous system. Its primary function is to potentiate glucose-stimulated insulin secretion postprandially, enhancing nutrient uptake and storage. Unlike GLP-1. GIP also promotes lipid deposition in adipose tissue, contributing to its dual role in energy metabolism.
Recombinant GIP proteins are engineered using biotechnological methods, such as expression in bacterial, yeast, or mammalian cell systems, to produce purified, bioactive forms of the hormone. These proteins retain the native structure and function of endogenous GIP, enabling research into its physiological and pathophysiological roles. Recombinant GIP has become a valuable tool for studying metabolic diseases, particularly type 2 diabetes and obesity, where GIP signaling is often dysregulated.
Recent therapeutic strategies explore GIP-based interventions, including GIPR agonists and antagonists. Notably, dual- or triple-target agonists (e.g., combining GIPR and GLP-1R agonism) have emerged as promising therapies, demonstrating superior efficacy in glycemic control and weight loss compared to single-target agents. For example, tirzepatide, a GIP/GLP-1 dual agonist, has shown groundbreaking results in clinical trials, highlighting GIP's therapeutic potential.
Overall, recombinant GIP proteins bridge basic research and clinical translation, offering insights into metabolic regulation and paving the way for novel treatments for diabetes, obesity, and related disorders.
×
